Bill Gates on Track to Grow His Fortune through Foundation’s Ties to Vaccine Makers

DEBATING COVID-19, 12 Oct 2020

Jeremy Loffredo | Children's Health Defense - TRANSCEND Media Service

8 Oct 2020 – A telling piece in The Nation this week reports some of the conflicts of interest the Bill & Melinda Gates Foundation holds in the world’s quest for a COVID-19 vaccine. According to the article, the foundation’s investments in companies working to develop COVID-19 vaccines put Gates “in a position to potentially reap considerable financial gains from the COVID-19 pandemic.”

The Nation cites the example of the foundation’s $40 million stake in CureVac, a German pharmaceutical company whose stock soared 400% after going public in August. A similar Nation article from earlier this year reported the Gates Foundation also holds corporate stocks and bonds in drug companies Merck, GlaxoSmithKline, Novartis and Sanofi, and the foundation gives these same companies charitable grants for projects like developing new drugs.

AstraZeneca, the British pharmaceutical company that gained an exclusive license to control the COVID-19 vaccine produced by Oxford University research, is considered a frontrunner in the vaccine race. According to The Nation: “Gates himself described his foundation as intimately involved in the partnership between AstraZeneca and the University of Oxford.” Gates had the leverage to push the university … because the foundation is one of the founders and largest funders of the Coalition for Epidemic Preparedness Innovations, which in turn funds the University of Oxford’s vaccine development (to the tune of some $384 million).”

AstraZeneca also received $750 million from the Global Alliance for Vaccines and Immunization, an organization the Gates Foundation helped set up and continues to fund to this day. Despite questions on the safety of the AstraZeneca vaccine, governments worldwide have already bought it, on the taxpayers dime.

Also notable is the Gates Foundation’s grants, totaling $20 million, to Moderna, whose vaccine has also been described as a COVID-19 frontrunner. The foundation has a “global health project framework agreement” with the company, agreeing to give it up to $100 million to develop its mRNA technology, in exchange for receiving “certain non-exclusive licenses,” which have yet to be publicly specified.

Even with all this, Gates doesn’t publicly disclose his conflicts of interest when appearing on TV as an expert on COVID-19. And, as The Nation reports, when Gates wrote an article in the New England Journal of Medicine, he simply listed his conflicts of interest as “numerous.” According to Forbes, Gates has seen his personal net worth increase by more than $10 billion since the onset of the pandemic.

Despite the Gates Foundation’s candid declaration to pursue “mutually beneficial opportunities” with vaccine manufacturers, it is rare to find reporting in mainstream media on the foundation’s conflicts of interest. This may be because the foundation funds a number of major media outlets, including NPR, BBC, ABC and Al Jazeera, as well as publications like The Daily Telegraph and the Financial Times. The Guardian’s entire “Global Development” section is made possible through a partnership with the Gates Foundation.

The foundation also invests in journalism training programs. According to the Seattle Times, “experts coached in Gates-funded programs write columns that appear in media outlets from The New York Times to the Huffington Post, while digital portals blur the line between journalism and spin.”

 

According to Robert F. Kennedy, Jr., chairman of Children’s Health Defense, The Nation’s exposé “is a refreshing change for those searching for critical reporting on the self-declared ‘biggest funder of vaccines in the world.’”

________________________________________________

Jeremy Loffredo is a reporter for Children’s Health Defense.

Go to Original – childrenshealthdefense.org


Tags: , , , , , , , , , , , , , , , , ,

 

Share this article:


DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.


There are no comments so far.

Join the discussion!

We welcome debate and dissent, but personal — ad hominem — attacks (on authors, other users or any individual), abuse and defamatory language will not be tolerated. Nor will we tolerate attempts to deliberately disrupt discussions. We aim to maintain an inviting space to focus on intelligent interactions and debates.

*

code

This site uses Akismet to reduce spam. Learn how your comment data is processed.